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Abstract Background Tumour necrosis factor-alpha (TNFa) has been found to be very effective in
the isolated limb perfusion setting for advanced extremity tumours. In a phase I study of
intrapleural administration of TNFa 5 patients were followed for inflammatory response
patterns.
Patients and methods Malignant mesothelioma patients were treated with repeated
intrapleural administration of 0·1–0·2 mg recombinant TNFa. Samples of serum and
pleural fluid were taken at different time-points before and after TNFa-administration.
Levels of TNFa, interleukin-6 (IL-6), interleukin-8 (IL-8), C-reactive protein (CRP) and
secretory phospholipase A2 (sPLA2) were measured using enzyme-linked immunosorbent
assays (ELISAs). Alpha 1-acid glycoprotein (a1-AG) was measured by nephelometry.
Results In pleural fluid TNFa and IL-8 reached peak levels, up to 50–700 ng mL¹1 and 6–
60 ng mL¹1, respectively, 24 h after administration of TNFa. IL-6 (peak levels up to
250 ng mL¹1) and sPLA2 peaked after 48 h. A slower and less dramatic pattern was observed
for the levels of CRP and a1-AG. In serum no detectable levels of TNFa and no IL-8 were
observed, whereas serum levels of IL-6, sPLA2 and CRP showed a clear increase after
intrapleural administration of TNFa. Cytokines and acute-phase proteins showed the same
pattern during subsequent cycles even up to 12 cycles. Tumour regression was not observed.
Conclusions In the setting of a phase I study of repetitive intrapleural administration of
TNFa in mesothelioma patients, we studied the characteristics of the inflammatory
response. Intrapleural administration was followed by a clear inflammatory response
locoregionally. In spite of TNFa peak levels as high as 700 ng mL¹1 systemic levels were
never detectable. The secondary cytokine response led to very high intrapleural IL-6 and IL-
8 levels. Systemically IL-8 levels were never detectable whereas high IL-6 levels were
induced systemically initially, with a decreased response to each intrapleural TNFa admin-
istration over time. The acute-phase response in contrast remained remarkably constant
throughout the course of repeated intrapleural administrations of TNFa. Intrapleural
administration of TNFa is well tolerated but associated with inconsistent and rather
moderate impact on production of pleural fluid. This can be achieved by other simpler
and cheaper treatment, thus we see no justification for further studies.
Keywords Acute-phase response, cytokine response, intrapleural immunotherapy,
mesothelioma, TNFa.
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Introduction
Malignant mesothelioma is a tumour associated with expo-
sure to asbestos [1]. Recent studies have indicated that the
incidence of malignant mesothelioma with its long time
between exposure and presentation of the disease will
continue to rise in the future [2].
Malignant mesothelioma is a notoriously refractory
tumour to all current treatments. Neither surgery [3] nor
radiotherapy [4,5] results in an increased survival. The
median survival of mesothelioma is about 10 months
[4,6,7]. Therefore various alternative approaches have
been tested [8]. Pleural mesothelioma tends to stay loco-
regionally throughout most of its natural course [9]. This
biological behaviour makes this disease amenable to loco-
regional administration of cytostatic agents or biologic
agents such as interferon-gamma (IFNg) [10], interferon-
alpha [11], IL-2 [12–14]. With intrapleural administration
of IFNg or IL-2 antitumour responses have been recorded
and it was speculated that TNFa might be implicated in
these antitumour effects. Thus we decided to explore
intrapleural administration of TNFa, a cytokine that had
failed systemic administration because of excessive toxicity
[15,16]. Therefore the clinical use of TNFa is restricted to
locoregional application. It is already very successfully used
in the treatment of irresectable sarcoma and melanoma
[17,18].
There are very few reports on intracavitary TNFa in
humans. TNF has been administered intraperitoneally in
patients with advanced peritoneal carcinomatosis [19,20].
Regional toxicity (abdominal pain) instead of systemic
toxicity was the dose-limiting factor in this setting. Intra-
pleural administration was studied in patients with malig-
nant pleural effusion by Karck et al. [21]. Treatment with
up to 200 mg/m2 weekly, led in 3 out of 6 patients to
disappearance of effusion. Because of this preclinical and
clinical data, we decided to perform a phase I study in
patients with stage I-IIA malignant pleural mesothelioma
with rTNFa to study the clinical effect on pleural meso-
thelioma and evaluate the inflammatory response after this
mode of administration.
We have previously shown [22] that leakage of TNFa
during isolated limb perfusion (ILP) caused an acute-phase
response. This was demonstrated by an increase of IL-6
directly after ILP until 2 days thereafter, followed by
increase of CRP, a1-AG and a1-antitrypsin after 1 day,
and decrease of negative acute-phase proteins albumin and
transferrin during ILP till 6 h after ILP.
In the literature it is questioned whether the acute-phase
protein response (APR) could be down regulated by a
repeated stimulus [23]. Clinical studies have shown that
in a number of chronic inflammatory diseases the APR is
less than would be expected for the activity of inflammation
[24–26]. In our patients a repeated stimulus is mimicked:
at regular time intervals, 2 weeks, TNFa is administered.
This enables us to investigate whether repeated administra-
tion of TNFa is still able to provoke an acute-phase
response.
Patients and methods
Patients
Five patients with pleural mesothelioma in a phase I study
were, respectively, sampled for evaluation of biologic
response patterns. Demographical and clinical character-
istics are summarised in Table 1. Staging and diagnosis of
mesothelioma was based on computerised tomographic
(CT) scan of the chest, thoracoscopic findings and histo-
logical examination of biopsy samples. According to
Butchart’s staging system [27] stage I is defined as
tumour confined within the capsule of the parietal pleura,
i.e. involving only ipsilateral pleura, lung, diaphragm
and external surface of the pericardium within pleural
reflection. Stage IIA is defined as mesothelioma invading
chest wall or mediastinal tissues with or without lymphnode
involvement ipsilaterally inside the chest.
Eligibility criteria required histologically confirmed
pleural mesothelioma stage I-IIA, sufficient pleural effu-
sion to insert an intrapleural catheter, no signs of loculation
on the CT scan, no prior chemo-, radio- or immuno-
therapy, age <76 years, Karnofsky performance status
$ 80%, no cardiovascular disease, a white blood cell
count $ 4·0 · 109 l¹1, platelets $ 100 · 109 l¹1, serum bili-
rubin and creatinine levels within the institution’s normal
range, no active infection, no use of corticosteroids and
obtained informed consent. The protocol was approved by
the hospital’s ethical committee.
Table 1 Patient characteristics and treatment response
Treatment Response
Patient no. Age Sex Stage after 6x after 12· Response
1 63 M I 1 · 0·1 mg – –
2 65 M I 12 · 0·1 mg SD PD
3 63 M IIA 18 · 0·2 mg SD SD-PD
4 65 M I 6 · 0·1 mg PD –
5 57 M I 6 · 0·1 mg PD –
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Treatment schedule
About 2 weeks before the first administration of TNFa a
Port-a-cath system was surgically inserted under general
anaesthesia. The correct intrapleural position was exam-
ined radiographically and a technetium-99 m colloid scan
was made to evaluate the distribution of pleural fluid
throughout the pleural cavity.
Recombinant human TNFa (Boehringer Ingelheim,
Germany) was administered as an intrapleural infusion,
repeated every 14 days. Four patients were treated with a
dose of 0·1 mg, one patient with 0·2 mg.
Tumour response evaluation
Response was evaluated after every 6 cycles using CT scan
of the chest. Tumour response and toxicity were assessed
according to the criteria of the World Health Organisation
(1979) [28]. In case of measurable disease, complete
response (CR) was defined as the disappearance of all
known disease for at least 4 weeks; partial response (PR)
as a decrease of >50% in tumour size for at least 4 weeks;
stable disease (SD) as a decrease of <50% in tumour size.
Progressive disease (PD) was defined as an increase of
> 25% in the diameter of any lesion or the appearance of
a new lesion.
Immunomonitoring and cytokine- and acute-phase
protein assays
Both serum samples and pleural fluid were collected at 4
time-points during each cycle: 24 h before administration
of TNFa, 24 h and 48 h after administration and at day 8.
All samples were cryopreserved until testing.
Levels of TNFa, IL-6, IL-8, CRP and sPLA2 were
measured using enzyme-linked immunosorbent assays
(ELISA). Used antibodies were obtained from the Central
Laboratory of the Blood Transfusion Service (Amsterdam,
the Netherlands).
For measuring TNFa, as described previously [29], flat-
bottomed microtitre plates (Nunc, Kamstrup, Denmark)
were coated overnight with purified monoclonal antibody
(MAb) against TNFa (CLB-TNF/7). After washing serial
dilutions of TNF-containing samples were added. Bound
TNFa was detected by biotinylated sheep anti-TNFa.
The detection limit of the assay was 5 pg mL¹1. Healthy
controls were below 5 pg mL¹1.
The IL-6 specific ELISA was described previously [30]. A
coat of CLB-IL-6/16 was applied overnight and bound IL-6
was detected by biotinylated affinity-purified polyclonal
sheep anti-IL-6. Lower detection limit was 1 pg mL¹1 and
normal healthy control subjects were below 10 pg mL¹1.
For IL-8 [31] a coat of CLB-IL-8/1 MAb was applied
overnight and bound IL-8 was detected by biotinylated
affinity-purified polyclonal sheep anti-IL-8. The lower
detection limit of this assay was 8 pg mL¹1. Normal
values were below 20 pg mL¹1.
CRP levels were measured by a sandwich ELISA using
polyclonal rabbit antihuman CRP Abs as catching Abs and
biotinylated MAb anti-CRP (CLB anti-CRP-2) as a
detecting Ab [32]. Results were referred to a standard
(Behringwerke AG, Marburg, Germany) and expressed
in mg L¹1. Detection limit was 10 ng L¹1.
The ELISA used for measuring sPLA2 was described
before [33]. Two different monoclonal antibodies against
human sPLA2 were used as coating and catching anti-
bodies, respectively. The lower limit of detection was
0·1 ng mL¹1. Normal healthy volunteers were below
5 ng mL¹1.
Levels of a1-acid glycoprotein were measured by
means of a nephelometric assay. Antisera were obtained
from the Central Laboratory of the Blood Transfusion
Service (Amsterdam, the Netherlands). Normal values
were 400–900 mg L¹1.
Results
Cytokine and acute-phase protein levels in pleural
fluid
Peak-levels (median with range) of cytokines and acute-
phase proteins of all patients are represented in Table 2. In
Figure 1 measurements of the first 6 cycles of patient 2
are depicted, the results of the other patients were compar-
able. After TNF-administration the concentration of
TNFa increased in 24 h to levels in the range of 50–
100 ng mL¹1. After 48 h still some TNFa was measurable
(150–500 pg mL¹1). No TNFa was measurable after 8
and 14 days. Before the first administration of TNFa IL-
6 was increased in all patients, values varying from 1200
to 80 000 pg mL¹1. It rose sharply to 100 ng mL¹1 after
24 h and 250 ng mL¹1 after 48 h. After 8 days it declined
to 30–80 ng mL¹1, after 14 days levels were in the range
of 15–33 ng mL¹1. IL-8 started at 180–260 pg mL¹1. It
increased sharply during in the first 24 h to 2–12 ng mL¹1,
then it decreased to 0·7–1·0 ng mL¹1 at 48 h and about
200 pg mL¹1 after 8 days. After 14 days levels were
around 150 pg mL¹1. Levels of CRP increased during
the first cycle from 3 mg L¹1 at start to 60 mg L¹1 after
8 days. Thereafter values remained constant around
60 mg L¹1. sPLA2 increased during 48 h from around
5 ng mL¹1 (3–9 ng mL¹1 after 24 h) to 20–30 ng mL¹1.
It decreased slowly over the following 2 weeks. Levels of
a1-AG remained constant around 1300 mg L¹1 after a
slow rise from 700 mg L¹1. The production of cytokines
demonstrated the same pattern even after cycle 12 in
patient 2.
Serum-cytokine and acute-phase protein levels
In serum (Fig. 2, Table 2) no TNFa and no IL-8 was
measurable in any patient. IL-6 could not be detected in
2 patients but rose sharply in the other 3, 24 h after
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TNF-administration; values were in the range of 125–
275 pg mL¹1. At 48 h it was still measurable in the first 4
cycles. In the course of treatment IL-6 levels gradually
decreased. Before the first administration of TNFa, CRP-
levels in serum were increased in all patients (31–
300 mg L¹1). CRP-levels increased slowly from around
100 mg L¹1 after 24 h to 500 mg L¹1 after 48 h. After 8
days CRP was still measurable: values in the range of
100 mg L¹1. After 14 days values were around 40 mg L¹1.
sPLA2 was increased after 24 and 48 h to about 30 ng mL
¹1
and 130 ng mL¹1, respectively. After a few cycles sPLA2
was also measurable after 8 days: about 7 ng mL¹1. a1-AG
was raised before administration of TNFa (1200–
2000 mg L¹1), it increased after 24 h after administration
to about 2500 mg L¹1 at day 8. After 14 days it was around
2000 mg L¹1.
Toxicity and tumour response
Five male patients were treated with intrapleural infusion of
TNFa. Stage I patients were treated with 0·1 mg and one
patient with stage IIA mesothelioma was treated with
0·2 mg. One patient received only one dose of TNFa:
Because of excessive pleural effusion, for which the patient
needed drainage of pleural fluid, complicated by a haema-
tothorax, further intrapleural TNF-administration could
not be pursued. The other 4 patients were evaluable for
toxicity and tumour response as they received a minimum
of 6 doses up to 18 doses. Overall tolerance was quite good.
All patients developed flu-like symptoms and mild
fever (38–39·3 8C) during 1–2 days. Two patients had a
short episode of nausea and vomiting. No grade III-IV
toxicity according to the WHO-criteria [28] was observed.
No hypotension or increase in heart rate was observed.
Furthermore, intrapleural TNFa had no effect on
number of leukocytes and thrombocytes, kreatinin and
liver functions.
None of the patients had a tumour response, only one
patient showed stable disease during 36 weeks. Of
note, once started with treatment none of the patients
needed drainage of pleural fluid any more. In 2 patients
dyspnea diminished obviously during treatment. Concern-
ing the other 2 patients: in one patient dyspnea did
not change and one patient did not have complaints of
breathlessness.
Table 2 Peak values (median, range) of measured cytokines and acute-phase proteins in 5 patients
Cytokine/ Acute-phase Serum Pleural fluid
Protein Pat Time Median Range Time Median Range
TNFa pg/mL 1* no peak <5 24 h 30000
2 no peak <5 24 h 51500 48000–118000
3 no peak <5 24 h 678000 190000–1755000
4 no peak <5 ND
5 no peak <5 24 h 2156000 218000–4395000
IL-6 pg mL¹1 1 24 h 160 day 8 179000
2 24 h 173 121–279 3 · 48 h,3 · 24 h 248000 187500–284000
3 no peak <1 no peak 18000–142000
4 no peak <1 ND
5† 24 h 113 91–135 24 h 286000 148500–393000
IL-8 pg mL¹1 1 no peak <8 24 h 6300
2 no peak <8 24 h 6000 2200–12400
3 no peak <8 24 h 64400 51000–71000
4 no peak <8 ND
5 no peak <8 24 h 186500 3500–261000
CRP mg l¹1 1 48 h 499 day 14 83
2 48 h 501 385–618 no peak 3–69
3 no peak 70–223 no peak 31–81
4 48 h 276 216–446 ND
5 48 h (2 · 24 h) 409 327–875 day 8 88 71–198
SPLA2 ng/mL 1 48 h 67 48 h 23
2 48 h 131 59–142 48 h 25 16–31
3 48 h 11 9–19 no peak 0·1–7
4 48 h 47 28–78 ND
5 48 h (3 · 24 h) 87 65–174 48 h 21 17–64
a1-AG mg l¹1 1 day 8 2420 ND
2 3xd8,3 · 48 h 2350 2090–2530 no peak 740–1560
3 no peak 1800–2610 ND
4 48 h 2440 2320–2630 ND
5 no peak 2100–2540 no peak 740–1620
*Only 1 cycle.
†IL-6 was measurable only during the first two cycles, thereafter it was under detection limit ND: not measured.
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Discussion
In the present study the biologic effects of intrapleural
administration of TNFa in patients with pleural
mesothelioma was studied. The results of the cytokine
measurements before administration of TNFa showed
signs of an ongoing inflammatory response. This was also
observed by others [34,35]. Before administration of
TNFa intrapleural levels of IL-6, IL-8, CRP, sPLA2 and
a1-AG were elevated. In serum we found increased levels
of CRP and a1-AG. Our measurements correspond to the
observations of Nakano et al. and Monti et al. The high
intrapleural IL-6 levels, before the first administration of
TNFa, appeared to be caused by production by the
mesothelioma-cells. IL-6 has been shown to be produced
by mesothelioma-cells in vitro [36,37]. IL-6, produced in
the pleural cavity, leaking to the systemic circulation, is
thought to be the responsible cytokine for the induction of
the acute-phase response. The mechanism of the acute-
phase response has been investigated and described earlier,
both in vitro [38,39] and in vivo [26,40,41].
Intrapleural administration of TNFa resulted in clear
IL-6, CRP, sPLA2 and a1-AG patterns in serum, with the
noticeable exception for TNFa and IL-8, which never
reached detectable levels systemically. This may be
explained by soluble receptors for TNFa and IL-8. With
respect to the IL-6 response in serum a significant increase
with a peak after 48 h was observed after each TNF-
administration. However the response diminished gradu-
ally in the course of time, most illustrative visible in
patient 2 in which no detectable IL-6 levels were observed
when TNFa had been administered more than 9 times.
This points to an ‘exhaustion’ phenomenon or a gradual
build-up of soluble IL-6 receptor levels.
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Figure 1 Cytokine (a) and acute-phase protein (b) profile in
pleural fluid during the first 6 cycles of intrapleural TNF-
administration in patient 2. Time-points: 24 h before
administration of TNFa, 24 h after TNF-administration, 48 h
after, and 8 days after. Day 14 is 24 h before the next gift of
TNFa.
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However, the acute-phase response was not diminished.
This may be explained by a direct stimulation of the acute-
phase response by TNFa and IL-1 [26,40]. TNFa and
IL-1 are only able to stimulate the positive acute-phase
proteins. So in our study (we only determined positive
acute-phase proteins) we could not distinguish which cyto-
kine had the most impact on the stimulation of the APR:
IL-6 or TNFa/IL-1. In contrast with the studies mentioned
above [24–26], we could not find a down-regulation of the
APR, even though the acute-phase response was already
activated before the first TNF-administration. Administra-
tion of TNFa did increase the levels of the acute-phase
proteins; this indicates that the APR was not maximally
stimulated before the first TNF-administration. A possible
explanation for the fact that we did not find a down-
regulation of the APR could be the relatively long
treatment free period of 2 weeks between the consecutive
administrations of TNFa.
TNFa had no antitumour effect in these 4 mesothelioma-
patients, but seemed to diminish pleural effusion. Reduction
of pleural fluid was also described before [21,42]. The
mechanism why TNF reduces pleural fluid is not quite
clear. Most likely, fluid production by mesothelioma cells
is reduced. Enhanced resorption of pleural fluid is less
likely as this mechanism would be associated with higher
systemic levels of TNFa and other cytokines, which we did
not observe.
In conclusion, intrapleural administration of TNFa was
followed by a clear inflammatory response locoregionally.
In spite of TNFa peak levels as high as 700 ng mL¹1
systemic levels were never detectable. The secondary cyto-
kine response led to very high intrapleural IL-6 and IL-8
levels. Systemically IL-8 levels were never detectable
whereas high IL-6 levels were induced systemically initially,
with a decreased response to each intrapleural TNFa
administration over time. The acute-phase response in
contrast remained remarkably constant throughout the
course of repetitive intrapleural administrations of TNFa.
Intrapleural administration of TNFa is well tolerated but
associated with a rather moderate impact on production of
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Figure 2 Cytokine (a) and acute-phase protein (b) profile
in serum during the first 6 cycles of intrapleural administration
of TNFa in patient 2. Time-points: 24 h before administration
of TNFa, 24 h after TNF-administration, 48 h after, and 8 days
after. Day 14 is 24 h before the next gift of TNFa.
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pleural fluid. As this effect can be achieved by other simpler
and cheaper treatment we see no justification for further
studies.
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